Jubilant Pharmova share news, announcements and annual reports
NSE: JUBLPHARMABSE: 530019Pharmaceuticals & BiotechnologySmall Cap
Jubilant Pharmova Limited · Formerly Jubilant Life Sciences · Face value ₹1 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jun 1981 on BSE, Jun 2003 on NSE
Last close ₹923.80down ₹22.20 (2.35%)BSE ₹924.70
Share price at the NSE close on 30 Oct 2026. Previous close ₹946.00.
30 Oct: open ₹946.00, high ₹951.80, low ₹920.00
52-week range of traded prices to 30 Oct 2026
₹786.05Low, 9 Mar 2026₹1,183.00High, 4 Nov 2025
- Next results date: the board meets on 13 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹14,714 Cr422nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 41.79
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹59 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 35.78
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.07
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.54%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 5.3%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹59 crore of one-off items, the largest of them in the quarter to Dec 2025.
- 6.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 7.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.45
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 56,22937.1% delivered
Jubilant Pharmova share news and announcements
1,152 announcements, routine notices left out, newest first. Page 19 of 24.
Oct 2011
25 Oct · Disclosure
At a meeting of the Compensation Committee of the Board of Directors held on October 24, 2011, 8,62,461 (Eight Lacs Sixty Two Thousand Four Hundred Sixty One) Options have been granted to eligible employees / directors of the Company and its subsidiaries, in accordance with JLL Employees Stock Option Plan, 2011. Each option shall entitle the holder to acquire 1 equity share of Re. 1 of the Company at a price of Rs. 200.05 per share.Since Jubilant Employees Welfare Trust is holding sufficient number of equity shares of the Company, it is envisaged to transfer the Shares from the Trust to beneficiaries upon exercise. As such, there would be no fresh issue of Shares by the Company and hence no dilution.24 Oct · Board meeting
To inter-alia consider and approve the Unaudited Financial Results of the Company for the quarter ended September 30, 2011.
Sep 2011
Aug 2011
9 Aug · Results
Consolidated Results for the quarter ended on 30-JUN-2011 as follows: Net Sales of Rs. 94429 lacs for quarter ending on 30-JUN-2011 against Rs. 98151 lacs for the quarter ending on 30-JUN-2010. Net Profit / (Loss) of Rs. 7712 lacs for the quarter ending on 30-JUN-2011 against Rs. 6273 lacs for the quarter ending on 30-JUN-2010.9 Aug · Results
Standalone Results for the quarter ended on 30-JUN-2011 as follows: Net Sales of Rs. 61702 lacs for quarter ending on 30-JUN-2011 against Rs. 68271 lacs for the quarter ending on 30-JUN-2010. Net Profit / (Loss) of Rs. 5389 lacs for the quarter ending on 30-JUN-2011 against Rs. 8019 lacs for the quarter ending on 30-JUN-2010.1 Aug · Board meeting
To inter-alia consider and approve the Unaudited Financial Results of the Company for the quarter ended June 30, 2011.
Jul 2011
29 Jul · Meeting
Register of Members/ Share Transfer Books of the Company will remain closed from August 12, 2011 to August 23, 2011 both days inclusive, for the purpose of Annual General Meeting and declaration of dividend, subject to the approval of members in the AGM to be held on August 23, 2011.6 Jul · Retirement of Director
Dr. Jag Mohan Khanna, Executive Director of the Company, has retired from the services of the Company on July 05, 2011. He ceases to be a Director of the Company also.
Jun 2011
May 2011
10 May · Dividend
Board of Directors of the Comapny at its meeting held on May 10, 2011 has recommended a dividend of Rs. 2 (Rupees Two) per share of Re. 1/- each. The dividend, if approved, by the Members at the Annual General Meeting, will be paid on or before September 22, 2011.10 May · Results
Standalone Results for the year ended on 31-MAR-2011 as follows: Net Sales of Rs. 220089 lacs for year ending on 31-MAR-2011 against Rs. 244620 lacs for the year ending on 31-MAR-2010. Net Profit / (Loss) of Rs. 27963 lacs for the year ending on 31-MAR-2011 against Rs. 36310 lacs for the year ending on 31-MAR-2010.10 May · Results
Consolidated Results for the year ended on 31-MAR-2011 as follows: Net Sales of Rs. 343340 lacs for year ending on 31-MAR-2011 against Rs. 378127 lacs for the year ending on 31-MAR-2010. Net Profit / (Loss) of Rs. 22972 lacs for the year ending on 31-MAR-2011 against Rs. 42146 lacs for the year ending on 31-MAR-2010.2 May · Board meeting
To inter-alia consider : (1) Audited Financial Results of the Company for the year ended March 31, 2011; (2) Recommendation of Dividend for the Year ended March 31, 2011.
Mar 2011
Feb 2011
14 Feb · Results
Consolidated Results for the quarter ended on 31-DEC-2010 as follows: Net Sales of Rs. 86647 lacs for quarter ending on 31-DEC-2010 against Rs. 96148 lacs for the quarter ending on 31-DEC-2009. Net Profit / (Loss) of Rs. 4411 lacs for the quarter ending on 31-DEC-2010 against Rs. 10080 lacs for the quarter ending on 31-DEC-2009.14 Feb · Results
Standalone Results for the quarter ended on 31-DEC-2010 as follows: Net Sales of Rs. 57957 lacs for quarter ending on 31-DEC-2010 against Rs. 61249 lacs for the quarter ending on 31-DEC-2009. Net Profit / (Loss) of Rs. 7142 lacs for the quarter ending on 31-DEC-2010 against Rs. 7057 lacs for the quarter ending on 31-DEC-2009.4 Feb · Board meeting
To inter-alia consider and approve the Unaudited Financial Results of the Company for the quarter ended December 31, 2010.
Jan 2011
Dec 2010
Nov 2010
29 Nov · Business
Jubilant Life Sciences Limited had informed the Exchange that as per the Scheme, Jubilant Industries Ltd. at the meeting of their Board of Directors held on November 26, 2010, has allotted 79,64,056 equity shares of Rs. 10 each as fully paid up, to the shareholders of Jubilant Life Sciences Ltd. in the ratio of 1 (One) equity share of Rs. 10 each of Jubilant Industries Ltd., for every 20 (twenty) equity shares of Re. 1 each held in Jubilant Life Sciences Ltd.The Company has now informed the Exchange that as per the Scheme, Jubilant Industries Ltd. at the meeting of their Board of Directors held on November 27, 2010, has allotted 79,64,056 equity shares of Rs. 10 each as fully paid up, to the shareholders of Jubilant Life Sciences Ltd. in the ratio of 1 (One) equity share of Rs. 10 each of Jubilant Industries Limited, for every 20 (twenty) equity shares of Re. 1 each held in Jubilant Life Sciences Limited.29 Nov · Business
As per the Scheme, Jubilant Industries Ltd. at the meeting of their Board of Directors held on November 26, 2010, has allotted 79,64,056 equity shares of Rs. 10 each as fully paid up, to the shareholders of Jubilant Life Sciences Ltd. in the ratio of 1 (One) equity share of Rs. 10 each of Jubilant Industries Ltd., for every 20 (twenty) equity shares of Re. 1 each held in Jubilant Life Sciences Ltd.19 Nov · Business
Jubilant Life Sciences Limited had informed the Exchange that the Scheme of Amalgamation and Demerger among Jubilant Life Sciences Limited, Speciality Molecules Limited, Pace Marketing Specialities Limited and Jubilant Industries Limited has been filed with Registrar of Companies and has become effective from November 15, 2010. The Company further informed the Exchange that, as envisaged in the Scheme, the Company has on November 18, 2010 allotted 5,01,364 equity shares of Re.1 each to the shareholders of Pace Marketing Specialities Limited.